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Abstract
Background: Estimates of the incidence and prevalence of chronic diseases can be made using
established cohort studies but these estimates may have lower reliability if based purely on self-
reported diagnosis.
Methods: The MRC Cognitive Function & Ageing Study (MRC CFAS) has collected longitudinal
data from a population-based random sample of 13004 individuals over the age of 65 years from 5
centres within the UK. Participants were asked at baseline and after a two-year follow-up whether
they had received a diagnosis of Parkinson's disease. Our aim was to make estimates of the
incidence and prevalence of PD using self-reporting, and then investigate the validity of self-
reported diagnosis using other data sources where available, namely death certification and
neuropathological examination.
Results:  The self-reported prevalence of Parkinson's disease (PD) amongst these individuals
increases with age from 0.7% (95%CI 0.5–0.9) for 65–75, 1.4% (95%CI 1.0–1.7) for 75–85, and 1.6%
(95%CI 1.0–2.3) for 85+ age groups respectively. The overall incidence of self reported PD in this
cohort was 200/100,000 per year (95%CI 144–278). Only 40% of the deceased individuals reporting
prevalent PD and 35% of those reporting incident PD had diagnoses of PD recorded on their death
certificates. Neuropathological examination of individuals reporting PD also showed typical PD
changes in only 40%, with the remainder showing basal ganglia pathologies causing parkinsonism
rather than true PD pathology.
Conclusion: Self-reporting of PD status may be used as a screening tool to identify patients for
epidemiological study, but inevitably identifies a heterogeneous group of movement disorders
patients. Within this group, age, male sex, a family history of PD and reduced cigarette smoking
appear to act as independent risk factors for self-reported PD.
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Background
A review of worldwide incidence figures for Parkinson's
disease (PD) was published in 2003[1]. This article cor-
rectly points out the major difficulties in comparing fig-
ures from one study to the next- namely differing methods
of case ascertainment, differing inclusion and exclusion
criteria and lack of follow up or histology to confirm diag-
noses. Age-specific rates for groups of patients over 65
years using similar methodologies find variable incidence
rates ranging from 29[2] to 222[3] per 100,000 per year.
Worldwide prevalence rates also vary due to differing
study methodologies, and comparisons are made even
more difficult due to international differences in general
population survival[4].
Studies that attempt to identify unrecognised cases within
the population using screening methods find higher inci-
dence and prevalence rates than studies using medical
records or death certificates. Studies of older cohorts iden-
tify much larger total numbers of PD patients, and gener-
ate more stable estimates of the disease frequency among
those people most at risk. Age-specific rates established
using similar methodologies among older groups of
patients find prevalence rates varying from a low of 198
per 100 000 in >50 year age group in China[5]. rising to
600 per 100,000 in 65–69 age groups, through to 3500
per 100 000 in 85–89 year age groups in Europe[6].
The MRC Cognitive Function in Ageing Study- CFAS is a
large prospective cohort study established in 1991 to
examine the frequency of cognitive dysfunction and eval-
uate possible risk factors for disturbed cognition amongst
the population over the age of 65 in the UK. Details of the
study have been previously published elsewhere. [7]. This
study has not sought to identify participants with unrec-
ognised symptoms of PD, but includes self-reported PD
status for all individuals. In this analysis, we present age
and sex specific figures for the self reported prevalence and
incidence of PD within CFAS participants over the first 2
years of follow up. We have also calculated prevalence and
incidence rates following standardisation to the 1991
European population age structure.
Self-reporting of PD status has lower precision for the
diagnosis than clinical assessment by a movement disor-
ders clinician[8], which in turn has a slightly lower preci-
sion for the diagnosis than neuropathological
examination[9]. In this study we have compared the fre-
quency of PD based on self-report with the frequency of
PD recorded on death certificates, and in a sample of our
patients we have been able to explore the accuracy of self-
reported PD status using post mortem neuropathological
diagnoses.
Methods
At each of 5 centres within the UK (Cambridgeshire,
North Wales (Gwynedd), Newcastle, Nottingham and
Oxford), random samples of approximately 2500 people
aged 65 years and above were recruited to this study (N =
13,004 total participants). A structured interview was per-
formed among all these individuals at baseline (S0),
including a question on PD diagnosis-see Figure 1. In
addition personal historical information was obtained
including quantitative assessment of cigarette smoking
and questions regarding a family history of PD. All partic-
ipants also completed the Mini-mental State examina-
tion[10], and a 20% sub-sample were selected for further
assessment at baseline (A0) including those participants
with obvious cognitive impairment. Participants were fol-
lowed up after 2 years for a further structured interview
(S2), or combined interview and assessment (C2).
Informant data regarding PD status (H2) were also sought
at follow-up. This study was approved by the Local
Research Ethics committee, the details are available on the
CFAS website[11].
Definition of prevalent PD patient
During the initial screening phase of the study (S0), par-
ticipants were asked the question- "Have you ever been
diagnosed with PD?" All questions were asked by lay
interviewers given standardised interview training for the
purposes of this study, but without clinical experience of
PD. These data therefore rely on self-reporting of PD sta-
tus by study participants. We have Yes/No information on
Schematic figure representing the design of the initial phases  of the CFAS study Figure 1
Schematic figure representing the design of the initial phases 
of the CFAS study.
Informant
Interview (H2) 
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12,652 of the 13,004 participants, which will be used as
the denominator figure for prevalence estimates.
Missing data and sensitivity analysis for PD prevalence 
estimate
Patients with missing data represent an important sub-
group at this stage. We have missing data for 352/13004
participants, the reasons for which have been coded as fol-
lows-"No Answer" (n = 8), "Not asked" (n = 4), "Data
Missing" (n = 340). Patients with missing data for this
question include a high proportion of those with cogni-
tive impairment, therefore we were concerned that this
group may include a disproportionately high number of
PD patients.
The (A0) assessment was performed on those patients
identified as having cognitive impairment at the preva-
lence screen (S0) and a random sample of normal subjects
(n = 2640). This number includes 32 patients self-report-
ing as suffering with PD as well as 234/352 of the patients
with missing data regarding PD diagnosis. This assess-
ment includes a section in which the lay interviewer rates
the participant for several possible clinical signs of PD-
"Slower Physically?", "Slow Movements?", "Expression-
less face?", "Parkinsonian Movements", "Monotonous
Voice?", and "Slow, Shuffling steps?" on a scale of "Not
present, Mild or Severe".
Using data from those individuals with complete Yes/No
data at S0 for the question "Ever diagnosed with PD", and
also included in the A0 assessment, we constructed logis-
tic regression models using Microsoft Stata to assess the
usefulness of these assessment variables in predicting self-
reported PD status. The best logistic regression model was
chosen based on maximising -model sensitivity + 2 ×
model specificity, (greater emphasis placed on specificity
to minimise false positive diagnoses). This model was fit-
ted to those individuals with missing data from the prev-
alence screen (S0), and who were included in the
assessment phase (A0), and the probability of their case
status evaluated.
The incidence of PD over 2 years
At the 2-year follow up interview, participants were asked
the question "Have you been diagnosed with PD in the
last 2 years?" An individual was considered an incident
case of PD if they,
1.Denied PD at S0- AND
2.Admitted PD at S2 (n = 24) -OR
3.Admitted PD at C2 (n = 7)- OR
4.Informant stated PD at H2, with subject information
(S2/C2) missing (n = 4)- OR
5.Information missing at S0 but "PD within 2 years at S2/
C2" (n = 0)- OR
6.Information missing at S0 & S2/C2 but "PD within 2
years" from informant (H2) (n = 0).
The total number of person years at risk (denominator)
was calculated for all individuals reaching the incidence
stage with complete data for PD status, who had not been
diagnosed with PD at S0. 4178 individuals (32%) were
lost to follow up from the study between the S0 and S2/
C2 stages, 1369 due to death (11%), 2621 refusal (20%)
and 144 moved away (1%). We do not know the exact
time point of the refusals or moved away groups hence
these individuals were censored, and except for the small
number of prevalent cases, we are unable to verify their
PD status. These individuals are not part of the numerator
or denominator for our PD incidence estimate.
The incidence of PD per 100 000 per year was calculated
for the 5 different regions in the study. Cambridgeshire
and Gwynedd can be considered predominantly rural
communities, in comparison with Newcastle, Oxford and
Nottingham, which represent more urban communities.
Results
The overall prevalence of PD identified within this study
for people aged over 65 years was 133/12652 = 1.05% (CI
0.87–1.2%). The age and sex specific figures for the prev-
alence of PD are presented in Tables 1 and 2, finding an
increasing prevalence of PD with increasing age as
expected, with consistently higher rates in men. There was
no significant difference in rates between rural and urban
communities. Age standardisation to the European 1991
population over the age of 65 years produces a prevalence
rate of 0.95% (CI 0.67–1.23%).
Using our sensitivity analysis, we sought to evaluate the
likely PD case status of 234 of the 352 patients with miss-
ing data at S0, and who had been assessed at A0. By max-
imising both sensitivity and specificity for PD case status
in our logistic regression models we were able to conclude
that 110/234 patients were very unlikely to have PD. Only
5/234 people were likely to be PD cases based on this
analysis. If we include this additional information in our
prevalence estimates, the overall prevalence increases to
138/12767 = 1.08% (CI 0.90–1.26%). Multi-variable
adjusted Odds Ratios for some of the putative risks for PD
among these self reported prevalent patients were calcu-
lated using logistic regression and are presented in Table
3.BMC Neurology 2006, 6:29 http://www.biomedcentral.com/1471-2377/6/29
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Incidence
Thirty five patients met our criteria for a self-reported inci-
dent PD case. The total number of person years at risk was
17,490, therefore our incidence estimate for self-reported
PD was 200/100 000/yr, CI (144,278). Standardisation of
the age-specific rates to the European 1991 population,
produced an age-standardised incidence rate among the
over 65s of 185/100 000/yr (95% CI 105–333).
There are small numbers of incident patients in each age
and sex subgroup therefore the confidence intervals for
these estimates are wide particularly in the very oldest age
group (Table 4 and 5). Nevertheless, there appears to be a
trend for increasing incidence of PD with advancing age
and in men. There was no significant difference in inci-
dence rates between the rural and urban regions.
All 5 of the patients thought to be "probable" prevalent
PD cases died prior to the incidence screen. Multi-variable
adjusted Odds Ratios for the same putative risks for PD
among these self reported incident patients are presented
in Table 6.
Death certification and neuropathological diagnosis of 
patients self-reporting PD
At the time of this analysis, 6415 participants were
deceased. 109/133 self-reported prevalent PD patients
were deceased. The number with PD recorded on either
part 1 or part 2 of their death certificates in this study was
44/109 (40%). Of the incident PD cases, 23/35 had died
at the time of this analysis. The number with PD recorded
on their death certificates was 8/23 (35%). 57 participants
who had not been identified as diagnosed with PD at
either the incident or prevalence screen also had PD
recorded on their death certificates (57/6282 = 0.9%). We
are unable to discriminate between these patients in
whom the diagnosis of PD was made after the incidence
screen and patients who had been diagnosed but did not
self-report PD diagnosis. Of these 57 individuals the
median time to death after S0 was 5.3 years (range 0.4–9.4
years), and among 24/57 who also participated in S2, the
median time from S2 to death was 4.4 years (range 0.5–
7.4 years). Approximately 25% of these individuals with
death certificate diagnosis of PD, died within 2 years of a
negative self report for PD.
Post mortem neuropathological examinations have been
performed on a representative sample of participants in
this study, including 10 brains from our patients self-
reporting PD. Four of these brains showed typical features
of PD, one brain had "insufficient Lewy bodies to make a
diagnosis of PD", and there was one each of -progressive
supranuclear palsy, Huntington's disease, basal ganglia
mineralisation, cerebral amyloid angiopathy, and possi-
ble Alzheimer's disease. There were a further four individ-
uals who had a neuropathological diagnosis of PD out of
a total of 339 brains examined from individuals who did
not report PD during the interview phases. The median
time between their last negative PD self report and death
was 3.0 years (range 0.8 years to 4.3 years).
Discussion
The frequency figures reported here have been based on
self-reported diagnosis of PD among a large population
based cohort of elderly people within the UK. This
method of detecting cases can potentially identify a
greater percentage of medically diagnosed patients than
using clinic or hospital records, since cases diagnosed
within the primary care setting and not referred for spe-
cialist opinion will not be missed. However, patients that
Table 1: Age and sex specific prevalence of self-reported PD in 
the CFAS study.
Age Group 65–74 75–84 85+ Total
Male 20/2808 33/1905 7/357 60/5070
0.7% 1.7% 2.0% 1.2%
CI 0.4–1.0 CI 1.1–2.3 CI 0.5–3.4 CI 0.9–1.5
Female 22/3486 36/3115 15/981 73/7582
0.6% 1.2% 1.5% 1.0%
CI 0.4–0.9 CI 0.8–1.5 CI 0.8–2.3 CI 0.7–1.2
All 42/6294 69/5020 22/1338 133/12652
0.7% 1.4% 1.6% 1.1%
CI 0.5–0.9 CI 1.1–1.7 CI 1.0–2.3 CI 0.9–1.2
Table 2: Prevalence of self reported PD in each of the 5 CFAS centres.
Cambridge Gwynedd Newcastle Nott'ham Oxford Total
Male 14/1098 8/1042 9/909 17/988 12/1033 60/5070
1.3% 0.8% 1.0% 1.7% 1.2% 1.2%
CI 0.6–1.9 CI 0.2–1.3 CI 0.4–1.6 CI 0.9–2.5 CI 0.5–1.8 CI 0.9–1.5
Female 10/1464 17/1509 14/1535 14/1452 18/1622 73/7582
0.7% 1.1% 0.9% 1.0% 1.1% 1.0%
CI 0.3–1.1 CI 0.6–1.7 CI 0.4–1.4 CI 0.5–1.5 CI 0.6–1.6 CI 0.7–1.2
All 24/2562 25/2551 23/2444 31/2440 30/2655 133/12652
0.9% 1.0% 0.9% 1.3% 1.1% 1.1%
CI 0.6–1.3 CI 0.6–1.4 CI 0.6–1.3 CI 0.8–1.7 CI 0.7–1.5 CI 0.9–1.2BMC Neurology 2006, 6:29 http://www.biomedcentral.com/1471-2377/6/29
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have not sought medical attention, or remain medically
undiagnosed can only be reliably identified in multi-stage
population screening studies. The S0 phase of the CFA
study was not designed to identify medically undiagnosed
PD cases, which therefore do not contribute to our preva-
lence and incidence estimates. Our sensitivity analysis
suggests however that large numbers of obvious prevalent
cases of PD have not been over-looked, although assess-
ments were performed by lay interviewers rather than
movement disorders specialists.
Acknowledging the possible non-identification of medi-
cally undiagnosed cases, our overall age standardised
prevalence figure of 0.95% can be compared to the overall
prevalence figure for PD of 1.6%, or for "parkinsonism" of
2.3%, identified in the EUROPARKINSON study of over
65s[6], that did use 2-phase screening methodology. Our
data confirm the increased prevalence of PD into the high-
est age groups and in men. Our age standardised inci-
dence figure for PD of 185/100 000 per year among over
65s, is comparable to the incidence figure of 250/100 000
per year among over 55s produced in the Rotterdam
study[12] that also used 2 stage screening methodology.
At the time of the incidence screen (S2), 11% of this eld-
erly cohort had died, and 20% refused to participate fur-
ther, and among these individuals we are unable to
quantify the number of cases of PD. Since PD symptoms
leading to physical or cognitive decline may be more fre-
quent among patients refusing participation, and are asso-
ciated with premature mortality, we acknowledge that our
incidence figure may be an under-estimate of the true inci-
dence of PD in this cohort.
In comparison to cases examined by movement disorders
specialists or investigated with functional imaging, self-
reporting of PD diagnoses is also likely to result in a low-
ering of diagnostic accuracy. Clinical diagnoses of PD are
only correct in 76–85% of cases even following assess-
ment by movement disorders specialists[9], and diag-
noses made within primary care will likely have even
lower validity[13]. Neuropathological diagnosis of PD is
considered the gold standard method of diagnosing PD
although there have hitherto been no population based
descriptive studies of the disease that include any neu-
ropathological confirmation of disease status. The limited
post-mortem data that we present in this study indicates
that self-reported PD status acts as a more useful guide to
presence of basal ganglia neuropathology rather than spe-
cific PD pathology. It is acknowledged therefore that the
loss of diagnostic specificity in population-based studies
such as this may impact on the analyses of potential risk
factors.
Phillips et al[14] have previously confirmed the incom-
plete reporting of PD on death certificates, finding that
Table 3: Analysis of risk factors for developing self-reported PD among prevalent patients.
Odds Ratio (OR) Multi-variable* adjusted OR
OR(95% CI) p value OR (95% CI) p value
Age group (per 10 years) 1.64 (1.29–2.08) <0.001 1.66 (1.29–2.13) <0.001
Male sex 1.23 (0.87–1.74) 0.23 1.53 (1.04–2.23) 0.029
Family history of PD 2.73 (1.69–4.42), <0.001 2.51 (1.50–4.20) <0.001
Current smoking 0.39 (0.21–0.72) 0.003 0.45 (0.24–0.85) 0.01
Ever smoking 1.00 (0.70–1.45) 0.97 1.32 (0.85–2.05) 0.21
Cigarette dose- per 10 pack-years 0.90 (0.82–0.99) 0.03 0.89 (0.80–0.98) 0.023
*Adjusted ORs are presented for the multivariable logistic regression model which includes all listed risk factors. (Only cigarette dose was included 
as the smoking covariate except in the evaluation of "current smoking" and "ever smoking".)
Table 4: Age and sex specific incidence of PD per 100 000 per year in the CFAS study.
Age Group 65–74 75–84 85+ All
Male 191/100 000/yr 351/100 000/yr 527/100 000/yr 266/100 000/yr
CI 96–382 CI 183–675 CI 132–2107 CI 170–417
(8 cases) (9 cases) (2 cases) (19 cases)
Female 78/100 000/yr 238/100 000/yr 194/100 000/yr 155/100 000/yr
CI 29–208 CI 128–442 CI 49–776 CI 95–253
(4 cases) (10 cases) (2 cases) (16 cases)
All 129/100 000/yr 281/100 000/yr 284/100 000/yr 200/100 000/yr
CI 73–227 CI 179–440 CI 107–756 CI 144–278
(12 cases) (19 cases) (4 cases) (35 cases)BMC Neurology 2006, 6:29 http://www.biomedcentral.com/1471-2377/6/29
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only 76% of PD cases who had had diagnoses confirmed
by neurologists had PD recorded in either Part 1 or 2 on
their death certificates. Pressley found that 55% of
patients had PD recorded on death certificates and there
was a dependence on social class[15]. In our population
study, it is not surprising that the percentage falls further,
since diagnoses made in primary care may not be availa-
ble for patients dying from unrelated causes in hospital,
and so PD diagnosis may not be completed on the certifi-
cate. We did not observe any alternative diagnoses that
might have caused extra-pyramidal symptoms, on the
death certificates of our patients. This study therefore
emphasises the inadequacy of only using routine mortal-
ity data in estimating disease frequency.
Analysis of several previously identified risk factors for PD
among our prevalent cases confirms previous associations
such as advancing age and male gender. A positive family
history of the disease is however the largest and most sig-
nificant risk factor (adjusted O.R. 2.5, p < 0.001). Inaccu-
rate self-reporting of diagnoses usually tends to dilute
rather than inflate observed risk factors for disease
although in this instance, individuals with a family his-
tory of PD might be at greater risk of false positive diag-
noses. A family history of PD has been previously
associated with younger onset forms of the disease and
our prevalent patients may include a small number with
young onset forms of the disease. Our incident patients
however represent a group of definite late onset patients
in whom we have collected "risk" data prior to their onset
of disease, which therefore should also be free from the
effects of differential recall bias. Among our incident cases
there is still an elevated OR for developing PD among
people with a positive family history of disease, although
the small numbers result in wider confidence intervals.
The results from this study give detailed frequency figures
for the incidence and prevalence of self reported PD
among a community-based population within the UK.
The study lends some epidemiological based support for
investigators searching for familial factors that increase
the risk of the common late onset forms of the disease, but
more importantly provides insight into the substantially
lower reliability of self-reported PD diagnosis in compar-
ison to the findings at post mortem examination.
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